Essity AB header image

Essity AB

ESSITY B

Equity

ISIN SE0009922164 / Valor 36851944

NASDAQ Nordic Exchange Stockholm, Equities (2026-03-27)
SEK 241.30-3.48%

Essity AB
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Essity AB is a global hygiene and health company headquartered in Sweden, known for its comprehensive range of products and solutions across various sectors. The company operates in three main business areas: Professional Hygiene, Health & Medical, and Consumer Goods. In Professional Hygiene, Essity provides sustainable hygiene management solutions, including dispensing systems for tissues, soaps, and sanitizers, as well as wiping and cleaning products tailored for commercial and public environments. The Health & Medical segment focuses on supporting patients, caregivers, and healthcare professionals with products and services in incontinence care, wound care, compression therapy, and orthopedics. In the Consumer Goods sector, Essity offers a wide array of personal and home hygiene products, such as baby care, feminine care, incontinence care, and consumer tissue products, catering to various life stages. Essity's commitment to innovation and sustainability is reflected in its diverse product offerings designed to enhance well-being and quality of life.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (26.03.2026):

Essity AB — Quarter 4, 2025 (and full-year 2025): In Q4 2025 Essity reported net sales of SEK 34,695m (down 8.2% y/y), organic sales -1.1%, EBITA SEK 5,005m (+9% y/y) and EBITA excl. IAC SEK 5,117m (+3% y/y) with an EBITA margin excl. IAC of 14.7% (up 1.6 pp). Profit for the period (total operations) was SEK 3,224m (Q4 2024: 2,893) and EPS was SEK 4.69 (4.13). For full-year 2025 net sales were SEK 138,494m (-4.8% y/y), organic sales +0.9%, EBITA SEK 19,503m (flat y/y) and EBITA excl. IAC SEK 19,572m (-4% y/y); profit for the period (total operations) was SEK 12,718m and EPS SEK 18.37. The Board proposes a 6% higher dividend to SEK 8.75 per share and the company continued a SEK 3bn buyback program.

Revenue and growth

Q4 net sales: SEK 34,695m (-8.2% y/y). Organic sales growth Q4: -1.1% (volume -0.2%, price/mix -0.9%). Full-year net sales: SEK 138,494m (-4.8% y/y) with organic growth +0.9% for 2025.

Profitability

Q4 EBITA: SEK 5,005m (+9% y/y). Q4 EBITA excl. IAC: SEK 5,117m (+3% y/y) and EBITA margin excl. IAC 14.7% (up 1.6 percentage points). Full-year EBITA: SEK 19,503m; EBITA excl. IAC SEK 19,572m (-4% y/y) and full-year EBITA margin excl. IAC 14.1% (up 0.1 pp).

Net income and EPS

Q4 profit for the period (total operations): SEK 3,224m (vs 2,893). Q4 EPS: SEK 4.69 (vs 4.13). Full-year profit for the period (total operations): SEK 12,718m (2024: 21,048; note large prior-year discontinued items) and full-year EPS SEK 18.37 (2024: 29.83).

Cash flow and leverage

Q4 operating cash flow: SEK 4,369m (Q4 2024: 3,297). Full-year operating cash flow: SEK 14,998m. Net cash flow, continuing operations in Q4: SEK 2,243m. Net debt at Dec 31, 2025: SEK 26,543m (down SEK 4,226m vs Dec 31, 2024). Net debt/EBITDA excl. IAC: 1.03.

Shareholder returns

Board proposes dividend up 6% to SEK 8.75/share (total ~SEK 5,977m based on outstanding shares at Dec 31, 2025). SEK 3bn buyback program continued in 2025 (total repurchased in 2025: 11,895,826 Class B shares for SEK 3,160m; Q4 repurchase 2,150,228 shares for SEK 555m). Repurchased shares held at year-end: 10,005,826 (≈1.4% of outstanding).

One-off items, costs and programs

Items affecting comparability (IAC) Q4: SEK -131m (mainly restructuring). Essity launched a cost savings program in Q4 targeting ~SEK 1bn annual savings (full effect by end-2026) with estimated restructuring costs ~SEK 1bn (SEK 71m recorded in Q4 2025).

M&A and organizational actions

On Nov 12, 2025 Essity agreed to acquire Edgewell’s feminine care business (brands including Carefree, Stayfree, Playtex); transaction expected to close Q1 2026. New organization effective Jan 1, 2026 and appointments to accelerate growth and supply‑chain enablement were announced.

Other notable metrics

ROCE (Q4) increased to 17.6% (15.8). Gross margin improvements cited (lower input costs and price management). Q4 tax rate ~27.5% (tax expense SEK 1,226m in Q4). Management highlights increased market shares for >65% of branded retail sales and continued sustainability recognitions.

Summarized from source with an LLMView Source

Key figures

-16.7%1Y
-18.3%3Y
-10.5%5Y

Performance

19.6%1Y
18.5%3Y
20.6%5Y

Volatility

Market cap

15915 M

Market cap (USD)

Daily traded volume (Shares)

1,734,580

Daily traded volume (Shares)

1 day high/low

297 / 293.6

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Intra-Cellular Therapies Inc
Intra-Cellular Therapies Inc Intra-Cellular Therapies Inc Valor: 23194616
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%USD 131.87
Denali Therapeutics Inc
Denali Therapeutics Inc Denali Therapeutics Inc Valor: 39149539
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-7.98%USD 18.16
GE Healthcare Technologies Inc
GE Healthcare Technologies Inc GE Healthcare Technologies Inc Valor: 123735674
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.23%USD 69.23
Option Care Health Inc
Option Care Health Inc Option Care Health Inc Valor: 52359365
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.73%USD 27.27
Boiron SA
Boiron SA Boiron SA Valor: 487646
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.56%EUR 26.00
Laboratorios Farmaceuticos Rovi, SA
Laboratorios Farmaceuticos Rovi, SA Laboratorios Farmaceuticos Rovi, SA Valor: 3591807
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.57%EUR 78.90
Roche Holding Ltd
Roche Holding Ltd Roche Holding Ltd Valor: 1203204
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.10%CHF 312.50
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc Madrigal Pharmaceuticals Inc Valor: 33395434
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.56%USD 510.68
Evotec SE
Evotec SE Evotec SE Valor: 505433
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.60%EUR 4.30
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc Syndax Pharmaceuticals Inc Valor: 24112479
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.90%USD 23.49